Hemophilia Treatment Market by Type (Hemophilia A, Hemophilia B), Treatment (Replacement Therapy, ITI Therapy, Gene Therapy), Therapy (Demand, Prophylaxis) - Analysis & Forecast 2019-2026
Report ID : 109 | Published Date : Jan 2020 | Pages : 210 | Region : Global | Report Code : PH-5
Hemophilia Treatment Market Overview and Introduction
Global hemophilia treatment market is estimated to be over US$ 11.2 Bn in 2018. It is anticipated to grow at 5.7% CAGR from 2019 to 2026.
Hemophilia is an inherited bleeding disorder in which the blood does not clot properly which leads to prolonged bleeding or oozing following an injury or surgery. There are several types of hemophilia amongst which hemophilia A and hemophilia B are the most common. Hemophilia A is caused by defective or absence of factor VIII whereas hemophilia B is caused due to lack or decrease of clotting factor IX. There are several treatments for hemophilia such as replacement therapy, ITI therapy and gene therapy. Replacement therapy is the most frequently used treatment for hemophilia. It involves use of clotting factors that are derived from human blood cells and recombinant clotting factors. Immune tolerance induction i.e. ITI therapy, is widely used to reduce complications arising from factor VIII (FVIII) replacement therapy in hemophiliac patients. Immune Tolerance Induction (ITI) therapy and replacement therapy are given in combination to the patients. Gene therapy is a relatively new therapy to treat hemophilia. It involves altering expression of genes in patients so as to establish normal functioning of defective gene.
The global hemophilia treatment market is driven by increasing prevalence of hemophilia and increasing availability of products for hemophilia diagnosis and treatment. Moreover, reimbursement offered by several government agencies and pharmaceutical companies in selected regions have contributed in extensive growth of the global hemophilia treatment market. However, confined access to clotting factor concentrates and cost effectiveness of hemophilia treatment are common factors to restrain the market to a certain extent.
Hemophilia Treatment Market by Type
On the basis of type, the hemophilia treatment market is segmented into hemophilia A, hemophilia B and others (Von Willebrand disease (VWD), Other Factor Deficiencies & Others). The hemophilia A segment is estimated to account for the largest share in the global hemophilia treatment market. The large share of this type segment can be attributed to higher prevalence of hemophilia A and severity associated with the same. Hemophilia A is considered to be four times more common than hemophilia B.
Hemophilia Treatment Market by Treatment
On the basis of treatment, the market can be segmented into replacement therapy, ITI (Immune Tolerance Induction) therapy and gene therapy. In terms of treatment, the segment of replacement therapy is estimated to account for the largest market share, owing to its increased preference by patients, extensive launch of new products and heavy investments in its research and development.
Hemophilia Treatment Market by Therapy
in terms of therapy the hemophilia treatment market can be segmented into demand and prophylaxis. The segment of prophylaxis, is estimated to grow at a robust CAGR during the forecast period owing to several factors such as it minimizes long-term issues associated with treatment, availability of novel longer-acting factor products, improves effectiveness of treatments and reduced frequency of dosage.
Hemophilia Treatment Market by Region
The global hemophilia treatment market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the market of hemophilia treatments, followed by Europe and Asia Pacific. North America will continue to dominate the global hemophilia treatment market in the forecast period owing to factors such rising incidence of hemophilia A and hemophilia B, increasing healthcare research facilities and growing recombinant coagulation factor concentrate products in the U.S. as well as Canada. However, Europe is expected to witness the highest CAGR owing to the rising prevalence of hemophilia A and increasing government support is expected to fuel the market in this region. Moreover, the technological advancements along with rising investments in research and development of new products for treatment of hemophilia are some of the principal factors that are expected to propel the growth of this market.
Hemophilia Treatment Market Prominent Players
The prominent players in the global hemophilia treatment market are Baxter, Grifols S.A., CSL Ltd., Novo Nordisk A/S, Kedrion S.p.A, Pfizer Inc., Bayer AG, Sanofi, Takeda, Octapharma and others.